The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations.
BRCA1
BRCA2
Basal cell carcinoma
Melanoma
Skin cancer
Journal
Hereditary cancer in clinical practice
ISSN: 1731-2302
Titre abrégé: Hered Cancer Clin Pract
Pays: Poland
ID NLM: 101231179
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
received:
18
01
2024
accepted:
02
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
It has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations. We report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations. Women were followed from the date of baseline questionnaire to the diagnosis of skin cancer, to age 80 years, death from any cause, or the date of last follow-up. During the mean follow-up period of eight years, 3.7% of women with a BRCA1 mutation (133 of 3,623) and 3.8% of women with a BRCA2 mutation (99 of 2,584) reported a diagnosis of skin cancer (including both keratinocyte carcinomas and melanoma). The cumulative risk of all types of skin cancer from age 20 to 80 years was 14.1% for BRCA1 carriers and 10.7% for BRCA2 carriers. The cumulative risk of melanoma was 2.5% for BRCA1 carriers and 2.3% for BRCA2 carriers, compared to 1.5% for women in the general population in the United States. The strongest risk factor for skin cancer was a prior diagnosis of skin cancer. The risk of non-melanoma skin cancer in women who carry a mutation in BRCA1 or BRCA2 is similar to that of non-carrier women. The risk of melanoma appears to be slightly elevated. We suggest that a referral to a dermatologist or primary care provider for BRCA mutation carriers for annual skin examination and counselling regarding limiting UV exposure, the use of sunscreen and recognizing the early signs of melanoma might be warranted, but further studies are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
It has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations.
METHODS
METHODS
We report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations. Women were followed from the date of baseline questionnaire to the diagnosis of skin cancer, to age 80 years, death from any cause, or the date of last follow-up.
RESULTS
RESULTS
During the mean follow-up period of eight years, 3.7% of women with a BRCA1 mutation (133 of 3,623) and 3.8% of women with a BRCA2 mutation (99 of 2,584) reported a diagnosis of skin cancer (including both keratinocyte carcinomas and melanoma). The cumulative risk of all types of skin cancer from age 20 to 80 years was 14.1% for BRCA1 carriers and 10.7% for BRCA2 carriers. The cumulative risk of melanoma was 2.5% for BRCA1 carriers and 2.3% for BRCA2 carriers, compared to 1.5% for women in the general population in the United States. The strongest risk factor for skin cancer was a prior diagnosis of skin cancer.
CONCLUSION
CONCLUSIONS
The risk of non-melanoma skin cancer in women who carry a mutation in BRCA1 or BRCA2 is similar to that of non-carrier women. The risk of melanoma appears to be slightly elevated. We suggest that a referral to a dermatologist or primary care provider for BRCA mutation carriers for annual skin examination and counselling regarding limiting UV exposure, the use of sunscreen and recognizing the early signs of melanoma might be warranted, but further studies are necessary.
Identifiants
pubmed: 38741145
doi: 10.1186/s13053-024-00277-5
pii: 10.1186/s13053-024-00277-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Investigateurs
Aletta Poll
(A)
Raymond Kim
(R)
Robert Fruscio
(R)
Edmond Lemire
(E)
Kim Serfas
(K)
Kevin Sweet
(K)
Leigha Senter
(L)
Seema Panchal
(S)
Christine Elser
(C)
Joanne L Blum
(JL)
Daniel Rayson
(D)
Claudine Isaacs
(C)
Jeffrey Dungan
(J)
Stephanie Cohen
(S)
Informations de copyright
© 2024. The Author(s).
Références
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol May. 2012;166(5):1069–80. https://doi.org/10.1111/j.1365-2133 .
doi: 10.1111/j.1365-2133
Global Cancer Observatory. Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr , accessed [01/13/2022]. 2020.
Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs Aug. 2013;29(3):160–9.
doi: 10.1016/j.soncn.2013.06.002
Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol Mar. 2016;74(3):395–407.
doi: 10.1016/j.jaad.2015.08.038
Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol Dec. 2014;20(36):4155–61.
doi: 10.1200/JCO.2014.58.2569
Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res Oct. 2006;15(20):9818–28.
doi: 10.1158/0008-5472.CAN-06-0494
Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet Feb. 2007;44(2):99–106.
doi: 10.1136/jmg.2006.043802
Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;03(1):77–90.
doi: 10.1007/s10555-017-9661-5
Read J, Wadt KA, Hayward NK. Melanoma genetics. J Med Genet Jan. 2016;53(1):1–14.
doi: 10.1136/jmedgenet-2015-103150
Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet May. 2014;46(5):478–81.
doi: 10.1038/ng.2947
Harland M, Petljak M, Robles-Espinoza CD, et al. Germline TERT promoter mutations are rare in familial melanoma. Fam Cancer Jan. 2016;15(1):139–44.
doi: 10.1007/s10689-015-9841-9
Molven A, Grimstvedt MB, Steine SJ, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer Sep. 2005;44(1):10–8.
doi: 10.1002/gcc.20202
Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet Mar. 2016;89(3):285–94.
doi: 10.1111/cge.12630
Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol Jul. 2020;47(7):606–16.
doi: 10.1111/cup.13689
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res Jan. 2012;15(2):400–7.
doi: 10.1158/1078-0432.CCR-11-2283
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.
doi: 10.1001/jama.2017.7112
pubmed: 28632866
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst Aug. 1999;91(15):1310–6.
doi: 10.1093/jnci/91.15.1310
Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11(2):235–42.
doi: 10.1007/s10689-011-9506-2
pubmed: 22187320
Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks Associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529–41.
doi: 10.1200/JCO.21.02112
pubmed: 35077220
pmcid: 9084432
Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC, Bray F. Global Burden of Cutaneous Melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495–503.
doi: 10.1001/jamadermatol.2022.0160
pubmed: 35353115
pmcid: 8968696
Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA Oct. 2005;05(13):1647–54.
doi: 10.1001/jama.294.13.1647
Slingluff CL, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surg Mar. 1993;113(3):330–9.
NCCN. Clinical Practice Guidelines in Oncology: Melanoma V3.2016.
Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer Jan. 2015;15(2):269–75.
doi: 10.1002/cncr.29041
Tuominen R, Engström PG, Helgadottir H, et al. The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility. Genes Chromosomes Cancer. 2016;07(7):601–11.
doi: 10.1002/gcc.22363
Dębniak T, Scott RJ, Górski B, Masojć B, Kram A, Maleszka R, Cybulski C, Paszkowska-Szczur K, Kashyap A, Murawa D, Malińska K, Kiedrowicz M, Rogoża-Janiszewska E, Rudnicka H, Deptuła J, Domagała P, Kluźniak W, Lener MR, Lubiński J. BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population. PLoS ONE. 2018;13(10).
Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA. Hereditary breast Cancer Clinical Study Group. BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer. 2010;9(4):489–93.
doi: 10.1007/s10689-010-9377-y
pubmed: 20809262
Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol May. 1994;30(5 Pt 1):774–8.
doi: 10.1016/S0190-9622(08)81509-5
Brenner DR, Ruan Y, Shaw E et al. Age-standardized cancer-incidence trends in Canada, 1971–2015. CMAJ. Nov 18 2019;191.
Tang E, Fung K, Chan AW. Incidence and mortality rates of keratinocyte carcinoma from 1998–2017: a population-based study of sex differences in Ontario. Can CMAJ. 2021;10:04.
Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer Sep. 2004;20(5):792–4.
doi: 10.1002/ijc.20322
Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer May. 2006;01(9):2285–92.
doi: 10.1002/ijc.21651
Levi F, Te VC, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol Jan. 2003;14(1):71–3.
doi: 10.1093/annonc/mdg028
NCCN. Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V2.2021.
Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol. 2015;172(6):1498–506.
doi: 10.1111/bjd.13626
pubmed: 25524463
pmcid: 5785081